Lantheus Holdings, Inc. — Q1 2022 Form 10-Q
Reporting period: Three months ended March 31, 2022. Unaudited results; comparisons are with Q1 2021 unless noted. Amounts are in millions except per-share data.
Business context and results
Lantheus develops, manufactures and sells imaging diagnostics, targeted therapeutics and AI solutions. It reports one operating segment. Q1 growth primarily reflected the commercial launch of PYLARIFY, which began in June 2021, and a $24.0 million Novartis license-related settlement payment recognized as revenue.
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Revenue | $208.9 | $92.5 | +125.8% |
| Gross profit / margin | $129.1 / 61.8% | $41.0 / 44.4% | Margin +17.4 percentage points |
| Operating income / margin | $58.9 / 28.2% | $15.6 / 16.9% | +277.2% income |
| Net income | $43.0 | $9.0 | +376.9% |
| Diluted EPS | $0.61 | $0.13 | |
| Operating cash flow | $10.3 | $9.8 | |
| Capital expenditures | $3.2 | $2.5 |
Revenue by category: PYLARIFY $92.8 million; precision diagnostics $86.2 million, including DEFINITY $58.3 million and TechneLite $22.6 million; strategic partnerships and other revenue $28.6 million. The latter includes the $24.0 million Novartis license revenue. DEFINITY revenue rose 4.2%; total precision diagnostics revenue was nearly flat.
Financial position and liquidity
- Cash and cash equivalents were $105.4 million at March 31, 2022, compared with $98.5 million at year-end. Cash, cash equivalents and restricted cash totaled $107.5 million.
- Total debt and other borrowings were $172.2 million carrying value, including $12.9 million current; principal obligations were $172.5 million. The term loan matures in June 2024; its stated interest rate was 2.2% at quarter-end.
- Current assets were $324.7 million and current liabilities $177.7 million. Current liabilities included $83.3 million of expected CVR payments.
- The company had a $200 million revolving credit facility maturing in June 2024 and reported compliance with its credit covenants. The filing does not clearly state the amount drawn or remaining borrowing availability.
- Operating cash flow was constrained by an $85.2 million increase in accounts receivable, attributed mainly to sales-order timing and a longer collection period. Management said cash, ongoing operating cash generation and continued revolver access should meet requirements over the next 12 months and beyond.
Material changes and unusual items
- Revenue increased $116.4 million, led by $92.8 million of PYLARIFY sales and the $24.0 million Novartis license revenue. The Novartis payment was received in April 2022, after quarter-end.
- General and administrative expense included an $18.4 million net expense from fair-value changes in contingent assets and liabilities, primarily reflecting revised revenue forecasts, market conditions, higher discount rates and passage of time. Contingent consideration liabilities rose to $104.2 million from $86.2 million, including $91.7 million for PYLARIFY CVRs.
- Q1 2021 included a $15.3 million gain on the Puerto Rico subsidiary sale and a $0.9 million gain on debt extinguishment; neither recurred in Q1 2022. These items affect comparisons of operating and other income.
- The effective tax rate was 25.8%, down from 37.2%, principally due to increased stock-compensation tax benefits; the filing cites state taxes and nondeductible contingency expense as factors above the statutory rate.
- The company received FDA approval in February 2022 to manufacture DEFINITY at its new in-house facility. A new supply agreement with JHS runs through December 2027.
Outlook, risks and contingencies
- No specific numerical revenue or earnings guidance is provided. Management expects liquidity to be sufficient for the next 12 months and beyond, subject to operating performance and financing access.
- PYLARIFY growth depends on FDA approvals for additional PET manufacturing facilities, production capacity, customer contracting, reimbursement and competitive positioning. Medicare transitional pass-through payment status began January 1, 2022 and is expected to expire December 31, 2024; subsequent reimbursement adequacy is uncertain.
- Competition includes approved PSMA imaging agents, with additional products in development. The filing also highlights potential DEFINITY generic competition despite later-expiring patents.
- Supply risks include reliance on third-party manufacturers and global Mo-99 suppliers, past supplier outages, and short shelf lives that require just-in-time radiopharmaceutical production. The SHINE supply facility was then expected to become operational in 2023, subject to approvals.
- Management reported that COVID-19 resurgences and hospital staffing constraints continued to affect operations; DEFINITY sales were believed to have been affected early in the quarter and improved later. Sustained inflation, supply-chain disruption and geopolitical events are also cited risks.
- PYLARIFY CVRs entitle holders to 40% of U.S. net sales above $100 million in 2022 and $150 million in 2023, subject to an aggregate cap currently estimated at approximately $100 million. Potential payments were expected as early as Q1 2023 and Q1 2024.
- A January 2022 global settlement with Novartis and affiliates resolved specified patent disputes and proceedings, included cross-licenses, and provided the $24.0 million payment. The company reported no material ongoing litigation in which it was a party as of March 31, 2022.
Investor verification priorities
- Assess PYLARIFY sales growth and margins excluding the one-time $24.0 million Novartis license revenue.
- Track receivable collections and operating cash flow, given the substantial quarter-end increase in accounts receivable.
- Verify PYLARIFY manufacturing-site approvals, supply capacity, customer access and reimbursement developments, especially after the 2024 pass-through period.
- Monitor CVR valuation, future cash payments and the resulting impact on liquidity.
- Confirm revolver utilization and availability, and the company’s ability to refinance or repay debt due in 2024.
- Follow DEFINITY competition and Mo-99 and third-party manufacturing continuity risks.